Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA HCC-206: pumitamig alone or with ipilimumab in first-line advanced hepatocellular carcinoma
2025-523602-33-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Pumitamig monotherapy with Pumitamig + ipilimumab (2 arms). Primary endpoints: Phase 1 safety and tolerability and Phase 2 objective response rate. Planned start May 2026; status: authorised.
02
Drugs
pumitamigipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2025-523602-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523602-33-00.